Kiniksa: Sanj K Patel proposes $51.6M share sale

The securities information also lists 48,836,965 shares outstanding, a separate figure from the proposed sale quantity.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) is identified as issuer in a notice listing a proposed sale, for Sanj K Patel's account, of 553,794 Class A ordinary shares, with an aggregate market value of $51,571,367.00. Charles Schwab & Co., Inc. is named as broker, and October 30, 2026 is listed as the approximate sale date.

The listed shares comprise 51,794 shares from a restricted stock lapse, 125,000 founders shares, and 377,000 shares from an employee stock-option exercise. The remarks state that options in the notice may be sold over various dates.

Key Figures

Proposed sale: 553,794 Class A ordinary shares Aggregate market value: $51,571,367.00 Shares outstanding: 48,836,965 shares +4 more

7 metrics

Proposed sale 553,794 Class A ordinary shares Shares listed for sale

Aggregate market value $51,571,367.00 Proposed sale

Shares outstanding 48,836,965 shares Figure listed in the securities information

Restricted stock lapse 51,794 shares Listed with the date March 16, 2022

Founders shares 125,000 shares Listed with the date October 15, 2015

Employee stock option exercise 377,000 shares Listed with the date October 30, 2026

Approximate sale date October 30, 2026 Date listed for the proposed sale

Key Terms

Restricted Stock Lapse, Founders Shares, Employee Stock Option Exercise, Cashless Exercise

4 terms

Restricted Stock Lapse financial

"Restricted Stock Lapse - see remarks"

Founders Shares financial

"Founders Shares"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

Employee Stock Option Exercise financial

"Employee Stock Option Exercise"

Cashless Exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares does Sanj K Patel propose to sell?

Sanj K Patel is listed as the person for whose account a proposed sale of 553,794 Class A ordinary shares is reported, with an aggregate market value of $51,571,367.00. Charles Schwab & Co., Inc. is named as broker, and October 30, 2026 is listed as the approximate sale date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 06:20 PM EDT Accepted by SEC EDGAR 10/30/2026 - 06:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001532218
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Patel Sanj K
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	553794	51571367.00	48836965	10/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	03/16/2022	Restricted Stock Lapse - see remarks	Kiniksa Pharmaceuticals, Ltd.			51794	03/16/2022	Equity Compensation
Class A Ordinary Share	10/15/2015	Founders Shares	Kiniksa Pharmaceuticals, Ltd.			125000	10/15/2015	N/A
Class A Ordinary Share	10/30/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			377000	10/30/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The shares reported in this filing were acquired and paid for between 03/16/2022 and 09/02/2023 and were sold in the Anglia Revocable Trust. Options in this filing may be sold over various dates.
Date of Notice	10/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	07/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sanj K Patel TTEE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)